Institute of Cancer Research Confidence in Concept (ICR CiC 2017)

Lead Research Organisation: Institute of Cancer Research

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description Chair of ESMO 2019 Multidisciplinary session: Is Randomisation of Clinical Trials still the Gold Standard? (ID 31)
Geographic Reach Europe 
Policy Influence Type Influenced training of practitioners or researchers
URL https://cslide.ctimeetingtech.com/esmo2019/attendee/confcal/session/calendar/2019-09-28
 
Description Deconstructing the sarcoma matrisome for drug target and biomarker discovery
Amount £120,000 (GBP)
Funding ID SUK02.2018 
Organisation Sarcoma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2019 
End 04/2022
 
Description Have received further funding from MC_PC_17163 following successful development of chemical matter. The products are currently been evaluated and an application for further funding from the MRC DPFS scheme is sought
Amount £93,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description Improving neoadjuvant therapy in high-risk sarcomas.
Amount £1,506,783 (GBP)
Funding ID 29363 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2020 
End 02/2025
 
Description TRANS-CASPS - Translational studies in the Cediranib in Alveolar Soft Part Sarcoma (CASPS) trial
Amount £120,000 (GBP)
Funding ID SUK03.2019 
Organisation Sarcoma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2020 
End 03/2024
 
Title Immunotranscriptomics for Radiotherapy Treated Rectal Cancer Patients 
Description We developed new pipelines of bioinformatics methods using transcriptomic data from rectal cancer samples collected before and after radiotherapy. 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? No  
Impact This tool helped us to identify immune changes before and after radiotherapy treatment in rectal cancer samples. 
 
Title Rectal cancer retrospective patient samples 
Description Retrospective rectal cancer patient samples from University of Leeds collaboration (Collaborator - Dr. Nick West) 
Type Of Material Biological samples 
Year Produced 2018 
Provided To Others? No  
Impact These samples helped us to understand the change in immune profiles between pre and post radiotherapy. 
 
Title Spatial profling 
Description Vectra based multiplex immunohistochemistry. This method was developed by Prof. Alan Melcher at the Institute of Cancer Research (ICR). 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? Yes  
Impact It helps in identifying different populations of immune cells in situ in patient samples. 
 
Description Currently developing folate receptor targeted anticancer drugs and are collaborating the CRUK Cancer Therapeutics Unit 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Currently developing folate receptor targeted anticancer drugs
Collaborator Contribution Provided funding to generate pilot data for a DPFS grant
Impact Currently in development
Start Year 2020
 
Description Genentech - PIM1 inhibitors 
Organisation Genentech, Inc
Country United States 
Sector Private 
PI Contribution On-going collaboration with Genentech to test 2 lead compound PIM1 inhibitors developed by them in triple-negative breast cancer models and using combinations of AKTi and chemotherapy with the PIM1 inhibitors.
Collaborator Contribution Genentech provided stocks of 2 inhibitors
Impact None as yet as initial testing is being carried out in vitro
Start Year 2019
 
Description Inflection Biosciences - PIM1 inhibitors 
Organisation Inflection Biosciences
Country United Kingdom 
Sector Private 
PI Contribution Testing of Inflection Biosciences IBL-100 series of PIM1 inhibitors in vitro
Collaborator Contribution Providing inhibitors for in vitro testing
Impact - Collaborations with Prof. Chris Lord, ICR for the successful ICR MRC CiC grant "Investigating PIM1 kinase inhibition as a combination strategy to sensitise basal-like and BRCA1 mutation associated Triple Negative Breast Cancer to therapy induced cell death and impair emergence of resistance" Awarded Sept 2018 for 1 year £83,500.
Start Year 2016
 
Description Neoadjuvant radiotherapy treated retrospective rectal cancer patient samples 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution Our contribution includes transcriptomics, bioinformatics and NanoString profiling along with the funding opportunity through MRC CiC.
Collaborator Contribution The partner provided retrospective and matched neoadjuvant radiotherapy treated rectal cancer patients samples before and after treatment with pathology information to provided responders and non-responders.
Impact Multidisciplinary collaboration involving clinical studies, bioinformatics and experimental biology. Poster presentation at THE 2ND CRICK INTERNATIONAL CANCER CONFERENCE, London in Sep 2019 - Title: Identification of novel immune targets in locally advanced rectal cancer (LARC) to improve response to chemo-radiation. ICRR 2019 Manchester, UK - Title: Radiotherapy/Immunotherapy combinations - the translational opportunities'?
Start Year 2018
 
Description Novartis PIM1 inhibitors 
Organisation Novartis
Department Novartis Pharmaceuticals UK Ltd
Country United Kingdom 
Sector Private 
PI Contribution On-going collaboration with Novarits around use of PIM1 inhibitors (lead candidate PIM447) in triple-negative breast cancer
Collaborator Contribution Novartis provided stocks of PIM447 for in vitro testing
Impact - Collaborations with Prof. Chris Lord, ICR for the successful ICR MRC CiC grant "Investigating PIM1 kinase inhibition as a combination strategy to sensitise basal-like and BRCA1 mutation associated Triple Negative Breast Cancer to therapy induced cell death and impair emergence of resistance" Awarded Sept 2018 for 1 year £83,500.
Start Year 2016
 
Description PIM1 as a synthetic lethal target for E-Cadherin loss-of-function from screen done in Bajrami et al (PMID: 29610289) 
Organisation Institute of Cancer Research UK
Department Division of Breast Cancer Research
Country United Kingdom 
Sector Academic/University 
PI Contribution - PIM1 as a synthetic lethal target for E-Cadherin loss-of-function from screen done in Bajrami et al (PMID: 29610289). Following up on PIMi combination drug screen hits relevant to this collaboration i.e. Crizotinib
Collaborator Contribution - PIM1 as a synthetic lethal target for E-Cadherin loss-of-function from screen done in Bajrami et al (PMID: 29610289) - developing preliminary data for future grant writing
Impact - PIM1 as a synthetic lethal target for E-Cadherin loss-of-function from screen done in Bajrami et al (PMID: 29610289)
Start Year 2018
 
Title Bioinformatics tools for immunotranscriptome analysis 
Description This allows to identify differentially expressed immune genes between pre and post radiotherapy samples. 
Type Of Technology Software 
Year Produced 2018 
Open Source License? Yes  
Impact This helped us to characterise immune profiles between pre and post radiotherapy samples. 
 
Description ASCO GI Poster presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact ASCO GI conference in San Francisco - Title - Characterisation of chemoradiation-induced changes in immune cells and targets for personalised therapy in locally advanced rectal cancer (LARC). Presenter -Elisa Fontana (Clinical PhD student)
Year(s) Of Engagement Activity 2019
URL https://ascopost.com/Meetings/?m=2019%20Gastrointestinal%20Cancers%20Symposium
 
Description Breast Cancer Now Divisional Tours 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact KD regularly takes part in tours of the BCN Division where she shows groups around the laboratory and present our research to a lay audience.
Year(s) Of Engagement Activity 2019,2020
 
Description Conference presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact ICRR 2019 Manchester, UK - Title: Radiotherapy/Immunotherapy combinations - the translational opportunities'? Presenter - Alan Melcher (Collaborator)
Year(s) Of Engagement Activity 2018
URL http://icrr2019manchester.com/
 
Description ICR Open Evening for Sixth Form Students 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact KD participated in the ICR Open Evening for sixth form students to learn about our research and careers in science.
Year(s) Of Engagement Activity 2019
 
Description NanoString Summit 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact NanoString Summit - Presenter - Anguraj Sadanandam (PI)
Year(s) Of Engagement Activity 2018
URL https://www.nanostring.com/company/events-archive/european-summit-London
 
Description Poster presentation - 1 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact THE 2ND CRICK INTERNATIONAL CANCER CONFERENCE, London in Sep 2019 where researchers across different biology disciplines attended. Presented by Anna Wilkins (Clinical PhD student)
Year(s) Of Engagement Activity 2019
URL https://www.crick.ac.uk/whats-on/the-2nd-crick-international-cancer-conference
 
Description Poster presentation - 2 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact 2 presentations - 3nd International Conference on Immunotherapy Radiotherapy Combinations, Paris, France - Characterisation of the immune response to short and long course neo-adjuvant radiotherapy (RT) in rectal tumours. Presenter - Anna Wilkins (Clinical PhD student) and Alan Melcher (Collaborator)
Year(s) Of Engagement Activity 2018
URL https://www.anticancerfund.org/en/international-conference-immunotherapy-radiotherapy-combinations
 
Description Presentation 2 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact 14th Annual Biomarker Congress - Presenter - Anguraj Sadanandam (PI)
Year(s) Of Engagement Activity 2019
 
Description School STEM Careers Event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact KD spoke at a school STEM careers event for GCSE students
Year(s) Of Engagement Activity 2019